Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Reproductive System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Reproductive System Neoplasm

Cancer Family

Reproductive System Neoplasm

CI-CAN-00000338Explore in graph →

Non-malignant3,042 active trials38 approved drugs197 evidence items

NCIt: C3674

Overview
Statistics
Survival
Genomics65
Variants & evidence197
Drugs58
Trials13672
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (625)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 526–550 of 625 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.
· Int J Clin Exp Med · 2015 · PMID 26629066 · validated civic_curation pubmed
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
· Lancet Oncol · 2017 · PMID 27908594 · validated civic_curation pubmed
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
· J Clin Oncol · 2015 · PMID 26324363 · validated civic_curation pubmed
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
· J Transl Med · 2016 · PMID 27154293 · validated civic_curation pubmed
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
· Br J Cancer · 2012 · PMID 23099803 · validated civic_curation pubmed
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.
· N Engl J Med · 2012 · PMID 22187960 · validated civic_curation pubmed
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
· J Clin Oncol · 2020 · PMID 32822286

Showing 526–550 of 625 publications

← Previous
1
…
21
22
23
24
25
Next →

· validated civic_curation

ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.

· Gynecol Oncol · 2019 · PMID 30797591 · validated civic_curation pubmed

Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.

· JCO Precis Oncol · 2023 · PMID 36753688 · validated civic_curation pubmed

Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations.

· J Clin Oncol · 2025 · PMID 39413348 · validated civic_curation pubmed

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.

· Onco Targets Ther · 2015 · PMID 26261420 · validated civic_curation pubmed

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

· Br J Clin Pharmacol · 2015 · PMID 26033044 · validated civic_curation pubmed

Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.

· Oncotarget · 2015 · PMID 26311741 · validated civic_curation pubmed

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

· Bone Marrow Transplant · 2010 · PMID 19648970 · validated civic_curation pubmed

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

· Gynecol Oncol · 2010 · PMID 19840887 · validated civic_curation pubmed

TP53 polymorphism, HPV infection, and risk of cervical cancer.

· Cancer Epidemiol Biomarkers Prev · 2001 · PMID 11535556 · validated civic_curation pubmed

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

· Int J Gynaecol Obstet · 2008 · PMID 18555254 · validated civic_curation pubmed

A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.

· Oncol Lett · 2013 · PMID 24137399 · validated civic_curation pubmed

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

· J Clin Oncol · 2015 · PMID 26324360 · validated civic_curation pubmed

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.

· J Clin Invest · 2016 · PMID 27159395 · validated civic_curation pubmed

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.

· Invest New Drugs · 2015 · PMID 26490654 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

· Clin Cancer Res · 2015 · PMID 25370471 · validated civic_curation pubmed

A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service.

· Front Pharmacol · 2014 · PMID 24782778 · validated civic_curation pubmed

Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.

· Cancer Chemother Pharmacol · 2009 · PMID 18607592 · validated civic_curation pubmed